ELDN Stock Analysis: Buy, Sell, or Hold?
ELDN - Eledon Pharmaceuticals, Inc. Common Stock
$2.21
-0.07 (-3.29%)
▼
5d:
+0.23%
30d:
+36.11%
90d:
-48.96%
BUY
HIGH Confidence
Last Updated: February 2, 2026
Earnings: Mar 19, 2026
Get Alerted When ELDN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ELDN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: ELDN shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: ELDN is currently trading at $2.21, which is considered slightly high relative to its 30-day fair value range of $1.68 to $2.21.
Technical Outlook: Technically, ELDN is in a downtrend. Immediate support is located at $2.06, while resistance sits at $2.33. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: ELDN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $8.00 (+250.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ELDN is in a downtrend. Immediate support is located at $2.06, while resistance sits at $2.33. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: ELDN has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $8.00 (+250.9%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Fair Price Range
$1.68 -
$2.21
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.2%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 250.9% below Wall St target ($8.00)
Fair Price Analysis
30-Day Fair Range
$1.68 -
$2.21
Current vs Fair Value
SLIGHTLY HIGH
Expected Move (7 Days)
±$0.29
(13.4%)
Support & Resistance Levels
Support Level
$2.06
Resistance Level
$2.33
Current Trend
Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-2.39
Wall Street Target
$8.00
(+250.9%)
Last updated: February 03, 2026 9:58 AM ET
Data refreshes hourly during market hours. Next update: 10:58 AM
Data refreshes hourly during market hours. Next update: 10:58 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ELDN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$66 | 58 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$112 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$93 | 60 HOLD |
|
RNA
Avidity Biosciences Inc |
STRONG BUY
15 analysts |
$75 | 61 BUY |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$108 | 55 HOLD |
